These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33648385)

  • 41. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
    Leung L; Liao S; Wu C
    ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CGRP inhibitors for migraine prophylaxis: a safety review.
    Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
    Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM; Olesen J
    Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.
    Wells-Gatnik WD; Pellesi L; Martelletti P
    Expert Rev Neurother; 2024 Nov; 24(11):1107-1117. PubMed ID: 39264231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
    Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
    Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
    Berger AA; Winnick A; Popovsky D; Kaneb A; Berardino K; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):163-188. PubMed ID: 33633424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
    Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
    Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
    Dubowchik GM; Conway CM; Xin AW
    J Med Chem; 2020 Jul; 63(13):6600-6623. PubMed ID: 32058712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
    van Hoogstraten WS; MaassenVanDenBrink A
    J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ubrogepant for the treatment of migraine.
    Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blocking CGRP in migraine patients - a review of pros and cons.
    Deen M; Correnti E; Kamm K; Kelderman T; Papetti L; Rubio-Beltrán E; Vigneri S; Edvinsson L; Maassen Van Den Brink A;
    J Headache Pain; 2017 Sep; 18(1):96. PubMed ID: 28948500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review.
    Ailani J; Kaiser EA; Mathew PG; McAllister P; Russo AF; Vélez C; Ramajo AP; Abdrabboh A; Xu C; Rasmussen S; Tepper SJ
    Neurology; 2022 Nov; 99(19):841-853. PubMed ID: 36127137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
    Johnston K; Powell LC; Popoff E; L'Italien GJ; Pawinski R; Ahern A; Large S; Tran T; Jenkins A
    J Med Econ; 2024; 27(1):627-643. PubMed ID: 38590236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
    Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
    Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine.
    Jinesh S
    Inflammopharmacology; 2023 Oct; 31(5):2245-2251. PubMed ID: 37421480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.